Senti Biosciences, Inc. beat EPS estimates 60% of the time across 10 reported quarters (6 beats, 4 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.33 | $-0.41 | -24.2% | Miss |
| Q12026 FY2026 | $-0.27 | $-0.36 | -33.3% | Miss |
| Q42025 FY2025 | $-0.43 | $-0.38 | +11.6% | Beat |
| Q42025 FY2025 | $-0.59 | $-0.69 | -16.9% | Miss |
| Q22025 FY2025 | $-0.90 | $-0.56 | +37.8% | Beat |
| Q12025 FY2025 | $-3.13 | $-0.67 | +78.6% | Beat |
| Q12024 FY2024 | $-0.23 | $-4.20 | -1726.1% | Miss |
| Q3 FY2023 | $-4.80 | $-4.20 | +12.5% | Beat |
| Q12023 FY2023 | $-4.70 | $-4.20 | +10.6% | Beat |
| Q42022 FY2022 | $-5.20 | $-3.80 | +26.9% | Beat |
| Q22022 FY2022 | — | $-2.70 | — | Miss |
| Q12022 FY2022 | — | $-2.50 | — | Miss |
Back to SNTI overview · SNTI holders · SNTI KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.